<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121341</url>
  </required_header>
  <id_info>
    <org_study_id>CEI/7</org_study_id>
    <nct_id>NCT01121341</nct_id>
  </id_info>
  <brief_title>ESOS (Endoscopic Saphenous Harvesting With an Open CO2 System) Trial</brief_title>
  <acronym>ESOS</acronym>
  <official_title>ESOS (Endoscopic Saphenous Harvesting With an Open CO2 System) Trial: a Prospective Randomized Trial for Coronary Artery Bypass Grafting (CABG) Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera San Giovanni Battista</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ESOS (Endoscopic Saphenous harvesting with an Open CO2 System) trial is a prospective&#xD;
      randomized trial for coronary artery bypass grafting (CABG) surgery to compare endoscopic&#xD;
      open CO2 harvesting system versus conventional vein harvesting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ESOS (Endoscopic Saphenous harvesting with an Open CO2 System) trial is a prospective&#xD;
      randomized trial for coronary artery bypass grafting (CABG) surgery to compare and to test&#xD;
      improvement in wound healing, quality of life, safety/efficacy, cost-effectiveness, short and&#xD;
      long-term outcomes and vein-graft patency after endoscopic open CO2 harvesting system versus&#xD;
      conventional vein harvesting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity hypothesis</measure>
    <time_frame>six weeks</time_frame>
    <description>When compared to Conventional vein-graft harvesting (CVH) in CABG surgery&#xD;
· Does Endoscopic vein-graft open CO2 system harvesting (EVOH) reduce postoperative wound complications (composite endpoint of all complications or individual complications) assessed with ASEPSIS score?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction hypothesis</measure>
    <time_frame>six weeks</time_frame>
    <description>· Does EVOH improve patient satisfaction, postoperative leg pain and quality of life assessed with VAS score and EUROQol-5D?&#xD;
To compare health-related quality of life for the two treatment arms (EVOH/CVH) by intention-to-treat&#xD;
To identify factors in addition to treatment assignment that are associated with variations in quality of life outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resource utilization hypothesis</measure>
    <time_frame>six weeks</time_frame>
    <description>When compared to Conventional vein-graft harvesting (CVH) in CABG surgery&#xD;
· Does EVOH affect resource utilization?&#xD;
Harvesting time related to the length of vein segments&#xD;
Harvesting closure time&#xD;
CABG time&#xD;
Mobility time&#xD;
Hospital length of stay&#xD;
Re-exploration for bleeding due to vein-graft bleed&#xD;
Readmission for leg wound complications&#xD;
Need for outpatient wound management resources&#xD;
To compare total medical costs for the two treatment arms (EVOH/CVH) by intention-to-treat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of vein harvesting hypothesis</measure>
    <time_frame>six weeks</time_frame>
    <description>When compared to Conventional vein-graft harvesting (CVH) in CABG surgery&#xD;
Do EVOH compromises the quality of venous conduit harvested?&#xD;
Number of harvested veins requiring repair&#xD;
Number of repairs to each vein&#xD;
Re-exploration for bleeding due to vein-graft bleed&#xD;
Histological integrity&#xD;
Specific secondary subanalysis adjusted for:&#xD;
Preparation solution of the vein conduit&#xD;
20 ml autologous blood&#xD;
0,5 ml heparin (5000UI/ml) = 2500 UI&#xD;
2 ml papavarine (30mg/ml) = 60 mg&#xD;
Uncontrolled distension pressure/ no touch technique harvesting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vein-graft patency hypothesis</measure>
    <time_frame>six weeks</time_frame>
    <description>Does EVH Open-CO2 system influence and improve vein-graft patency?&#xD;
Assessment of systemic carbon dioxide absorption with respiratory and hemodynamic parameters&#xD;
Assessment of vein-graft patency with:&#xD;
vein conduit quality [diameter/well thickness]&#xD;
vein segments above/below the knee&#xD;
target coronary artery grafted territory&#xD;
target coronary artery diameter&#xD;
target coronary artery stenosis&#xD;
target coronary artery severity disease&#xD;
ascending aorta disease&#xD;
composite /uncomposite graft&#xD;
left ventricular function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>outcome hypothesis</measure>
    <time_frame>18 months</time_frame>
    <description>§ Detection of long-term outcomes:&#xD;
MACE (major adverse cardiac events): death; myocardial infarction; revascularization (PCI or CABG) for ischemia or angina recurrence&#xD;
MACE related to vein-graft failure&#xD;
GF (vein-graft failure): at least 75% of stenosis;&#xD;
GO (vein-graft occlusion) at angiographic study&#xD;
to identify factors in addition to treatment assignment that are associated with variations in long-term outcomes and graft patency&#xD;
baseline demographic characteristics and medications used of two treatment arms (EVOH/CVH)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Bypass Grafting Surgery</condition>
  <arm_group>
    <arm_group_label>EVOH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure: Endoscopic vein with an open CO2 system harvesting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OVH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure: Conventional vein harvesting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vein harvesting</intervention_name>
    <description>Endoscopic versus conventional vein harvesting</description>
    <arm_group_label>EVOH</arm_group_label>
    <arm_group_label>OVH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective planned CABG surgery&#xD;
&#xD;
          -  First isolated CABG surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency revascularization: patients with hemodynamic instability or requiring&#xD;
             inotropic or intra-aortic balloon support&#xD;
&#xD;
          -  Previous cardiac surgery&#xD;
&#xD;
          -  Planned concomitant valve surgery&#xD;
&#xD;
          -  Very varicous veins&#xD;
&#xD;
          -  Previous saphenectomy&#xD;
&#xD;
          -  History of deep vein thrombosis&#xD;
&#xD;
          -  History of suffered trauma on the lower extremity&#xD;
&#xD;
          -  Preoperative legs immobilization&#xD;
&#xD;
          -  Previous leg wound complications&#xD;
&#xD;
          -  Coexisting illness with life expectancy &lt; five years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Campanella, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Thoracic and Cardiovascular Surgery, San Giovanni Battista of Turin Hospital, Corso Bramante 88/90, 10126 Turin, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauro Rinaldi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic and Cardiovascular Surgery, San Giovanni Battista of Turin Hospital, Corso Bramante 88/90, 10126 Turin, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Campanella, MD</last_name>
    <phone>+39 011 633 55 11</phone>
    <email>antoniocampanella@libero.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino</name>
      <address>
        <city>Turin</city>
        <state>Piedmont</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Campanella, MD</last_name>
      <phone>+39 011 633 55 11</phone>
      <email>antoniocampanella@libero.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Campanella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauro Rinaldi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>May 19, 2010</last_update_submitted>
  <last_update_submitted_qc>May 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Silvana Barbaro and Serenella Scipioni</name_title>
    <organization>Azienda Ospedaliera San Giovanni Battista</organization>
  </responsible_party>
  <keyword>Endoscopic vein harvesting</keyword>
  <keyword>Saphenous vein</keyword>
  <keyword>Conventional vein harvesting</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

